Abstract
A topological substructural molecular design approach (TOPS-MODE) has been used to formulate structural rules for binding of substrates of P-glycoprotein (P-gp). We first review some of the models developed in the recent literature for predicting binding to Pgp. Then, we develop a model using TOPS-MODE, which is able to identify 88.4% of substrates and 84.2% of non-substrates. When the model is presented to an external prediction set of 100 substrates and 77 nonsubstrates it identifies correctly 81.8% of all cases. Using TOPS-MODE strategy we found structural contributions for binding to P-gp, which identifies 24 structural fragments responsible for such binding. We then carried out a chemico-biological analysis of some of the structural fragments found as contributing to P-gp binding of substrates. We show that in general the model developed so far can be used as a virtual screening method for identifying substrates of P-gp from large libraries of compounds.
Keywords: TOPS-MODE, knowledge generation, P-glycoprotein, QSAR, molecular modeling, Spectral Moments, graph-theory descriptors, DEREK, TOPKAT, natural detoxification system, (MDRR), linear discriminant analysis (LDA), Automated Rule-Extraction, Randi, ’, s method, biophore, TSET, PSET, P-gp Efflux, MULTICASE, orthogonalization
Current Pharmaceutical Design
Title: Structural Contributions of Substrates to their Binding to P-Glycoprotein. A TOPSMODE Approach
Volume: 16 Issue: 24
Author(s): Ernesto Estrada, Enrique Molina, Delvin Nodarse and Eugenio Uriarte
Affiliation:
Keywords: TOPS-MODE, knowledge generation, P-glycoprotein, QSAR, molecular modeling, Spectral Moments, graph-theory descriptors, DEREK, TOPKAT, natural detoxification system, (MDRR), linear discriminant analysis (LDA), Automated Rule-Extraction, Randi, ’, s method, biophore, TSET, PSET, P-gp Efflux, MULTICASE, orthogonalization
Abstract: A topological substructural molecular design approach (TOPS-MODE) has been used to formulate structural rules for binding of substrates of P-glycoprotein (P-gp). We first review some of the models developed in the recent literature for predicting binding to Pgp. Then, we develop a model using TOPS-MODE, which is able to identify 88.4% of substrates and 84.2% of non-substrates. When the model is presented to an external prediction set of 100 substrates and 77 nonsubstrates it identifies correctly 81.8% of all cases. Using TOPS-MODE strategy we found structural contributions for binding to P-gp, which identifies 24 structural fragments responsible for such binding. We then carried out a chemico-biological analysis of some of the structural fragments found as contributing to P-gp binding of substrates. We show that in general the model developed so far can be used as a virtual screening method for identifying substrates of P-gp from large libraries of compounds.
Export Options
About this article
Cite this article as:
Estrada Ernesto, Molina Enrique, Nodarse Delvin and Uriarte Eugenio, Structural Contributions of Substrates to their Binding to P-Glycoprotein. A TOPSMODE Approach, Current Pharmaceutical Design 2010; 16 (24) . https://dx.doi.org/10.2174/138161210792389243
DOI https://dx.doi.org/10.2174/138161210792389243 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Advances in the Molecular Pathogenesis of Inflammatory Bowel Disease.
This thematic issue will emphasize the recent breakthroughs in the mechanisms of Inflammatory bowel disease (IBD) pathogenesis and devotes some understanding of both Crohn’s and ulcerative colitis. It is expected to include studies about cellular and genetic aspects, which help to precipitate the disease, and the immune system-gut microbiome relations ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
Food-derived bioactive peptides against chronic diseases
Chronic diseases, such as cardiovascular diseases and metabolic diseases, have become a great threat to the human health in recent decades due to the excessive food consumption and the prevalence of sedentary lifestyle. As a class of natural compounds, food-derived bioactive peptides have been demonstrated to possess great potential for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Chlorophyll Catabolite Pheophorbide a as a Photosensitizer for the Photodynamic Therapy
Current Medicinal Chemistry Bone Morphogenetic Protein-Smad Pathway as Drug Targets for Osteoporosis and Cancer Therapy
Endocrine, Metabolic & Immune Disorders - Drug Targets New Approaches in Glioblastoma Multiforme: The Potential Role of Immune- check Point Inhibitors
Current Cancer Drug Targets Moving to the Rhythm with Clock (Circadian) Genes, Autophagy, mTOR, and SIRT1 in Degenerative Disease and Cancer
Current Neurovascular Research Stimuli-responsive Carriers for Controlled Intracellular Drug Release
Current Medicinal Chemistry Mechanisms of Angiogenesis: Perspectives from Antiangiogenic Tumor Therapies
Current Angiogenesis (Discontinued) Emerging Risk Factors for Cerebrovascular Disease
Current Drug Targets The Role of Melanocortin Peptides and Receptors in Regulation of Energy Balance
Current Pharmaceutical Design (Neuro)Transmitter Systems in Circulating Immune Cells: A Target of Immunopharmacological Interventions?
Current Medicinal Chemistry Neural Plasticity After Spinal Cord Injury
Current Pharmaceutical Design New Antiviral Nucleoside Prodrugs Await Application
Current Medicinal Chemistry Oxidative/Nitrosative Stress and Immuno-inflammatory Pathways in Depression: Treatment Implications
Current Pharmaceutical Design Flavonoids as Sirtuin Modulators
Current Topics in Medicinal Chemistry Recent Patents Review in Microencapsulation of Pharmaceuticals Using the Emulsion Solvent Removal Methods
Recent Patents on Drug Delivery & Formulation Immunity Modulators, Repurposed Drugs and Candidate Vaccines for COVID-19: A Review
Coronaviruses Protein Folding Assisted by Chaperones
Protein & Peptide Letters Ulcerative Colitis: Pathogenesis
Current Drug Targets Resistance to Crizotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) with ALK Rearrangement: Mechanisms, Treatment Strategies and New Targeted Therapies
Current Clinical Pharmacology Brief Hyperthermia Does not Worsen Outcome after Striatal Hemorrhage in Rats
Current Neurovascular Research Developments in Thermometry from 1984 to 2011: A Review
Recent Patents on Mechanical Engineering